Barozzi N, Sturla S. Clinical Evidence for Herb-Drug Interaction in Chemotherapy (2014)(draft)
Tett SE, Sketris I, Cooke C, van Zanten SV, Barozzi N. Differences in utilization of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada Pharmacoepidemiol Drug Saf (2013)
Barozzi N., Tett S Gastro-protective drugs in Australia: ten-year utilization pattern in relation to non-steroidal anti-inflammatory drug prescription. Clin Ther (2009); 31:849-61
Barozzi N, Ingrid Sketris I, Charmaine Cooke C, Tett SE. Comparison of Non-Steroidal Anti-Inflammatory Drugs and Cox-2 Inhibitors Use In Australia And Nova Scotia (Canada) British Journal of Clinical Pharmacology (2009); 68(1):106-15
Barozzi N., Tett S Non-steroidal anti-inflammatory drugs Cyclooxygenase-2 Inhibitors and paracetamol use in Queensland and in the whole of Australia BMC Health Serv Res (2008); 8:196
Barozzi N., Tett S Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market. Clin Rheumatol 28(5):509-19
Abdel-Aal ABM, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I. Structure–Activity Relationship of a Series of Synthetic Lipopeptide Self-Adjuvanting Group A Streptococcal Vaccine Candidates J Med Chem (2008); 51(1):167-72
Barozzi N., Tett S. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf (2007); 16(11):1184-91
Olive C, Ho MF, Dyer J, Lincoln D, Barozzi N, Toth I, et al. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis (2006);193(12):1666-76
Moyle PM, Olive C, Karpati L, Barozzi N, Ho MF, Dyer J, et al. Synthesis and immunological evaluation of M protein targeted tetra-valent and tri-valent group A streptococcal vaccine candidates based on the lipid-core peptide system. International J Peptide Res Ther (2006); 12(3):317-26.
Everett RS, Vanhook MK, Barozzi N, Toth I, Johnson LG. Specific modulation of airway epithelial tight junctions by apical application of an occludin peptide. Molecular Pharmacol (2006); 69(2):492-500.
Barozzi N, Tett SE. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther (2009); 31(4):849-61.
Moyle PM, Barozzi N, Wimmer N, Olive C, Good M, Toth I. Development of peptide vaccines against HPV-16 associated cervical cancer and Group A Streptococci. Biopolymers (2005); 80(4):556-7
Abstracts & Conference presentations
Barozzi N., Tett S. Impact of rofecoxib withdrawal and lumiracoxib introduction on the overall COX-2 inhibitors utilization in Australia international Conference of Pharmacoepidemiology (ICPE), Copenhagen, Denmark (August 17th – 22nd 2008)
Barozzi N., Tett S. Comparison of non-steroidal anti-inflammatory drugs and COX-2 inhibitors use in Australia and Nova Scotia (Canada) Conference of Pharmaceutics and Therapeutics (CPT), Quebec City (Canada) (July 27th – August 1st 2008)
Barozzi N., Tett S. Gastro-protective drugs in Australia: ten year utilization pattern in relation to non-steroidal anti-inflammatory drug prescription. National Medicine Symposium (NMS), Canberra, Australia (May 14th – 16th 2008)
Barozzi N, Tett SE. Cox-2 inhibitor influence on non-steroidal anti-inflammatory drug (NSAIDs) and paracetamol use in 6 countries. Pharmacoepidemiology and Drug Safety 2007;16:S80-S
Barozzi N., Tett S. Perceived barriers to acetaminophen prescribing, especially following rofecoxib withdrawal from the market. Canadian Therapeutics Congress (CTC) Halifax, Nova Scotia, Canada (May 27th – 31th 2007)
Barozzi N., Tett S, Evaluating how guidelines for replacement therapy were implemented following withdrawal of rofecoxib. National Institute of Clinical Studies (NICS) Using Evidence: Using Guidelines Symposium 19 & 20 October 2006, Melbourne
Barozzi N, Tett S. Non-steroidal anti-inflammatory drug prescription in relation to the prescribing of gastroprotective drugs in Australia. Pharmacoepidemiology and Drug Safety 2006;15:S158-S9.
Barozzi N, Tett S. How did rofecoxib withdrawal influence overall non steroidal anti-inflammatory drug (NSAIDs) and paracetamol prescribing in Australia? In: NMS, 2006; Canberra
Barozzi N, Tett S. Use of non selective non steroidal anti-inflammatory drugs, COX-2 inhibitors and Paracetamol. In: APSA-ASCPT, 2005; Melbourne
Istvan Toth, Aniko Horvath, Levente Karpati, Peter Moyle, Nadia Barozzi, Colleen Olive, Michael Good, design and development of novel vaccine adjuvant/carrier systems, 17th Singapore Pharmacy Congress Inter-varsity pharmacy symposium. (July 1st-4th 2005) Grant Copthorne Waterfront Hotel Singapore
Istvan Toth, Peter M Moyle, Nadia Barozzi, Colleen Olive, Michael Good, Liposaccharides in drug and vaccine delivery. Symposium (2005), Future Materials for Life Sciences: Drug Delivery, presented by Future Materials, AIBN, RACI QLD branch and UQ, IMB 16 May 2005.
A Horvath, C Olive, N Barozzi, L Karpati, MF Good, I Toth, A synthetic Group A Streptococcal vaccine of high purity and broad protective range. Indo-Australian Conference on Biotechnology in Infectious Diseases, MAHE Manipal, March 1-3, 2005 page 95, P-63
Barozzi N, Geiger M, Friess W. Evaluation of the USP Drug Release Test Apparatus 4 For Characterization of rhBMP-2 Loaded Implantable Carriers. In: Local Chapter Germany Meeting. Saarbruecken: Controlled Release Society; 2001